Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from N4 Pharma ( (GB:N4P) ) is now available.
N4 Pharma plc, the UK biotech behind the Nuvec gene delivery system for cancer and other advanced therapies, is repositioning itself as a therapeutics-focused biotechnology business with an expanded pipeline of RNA-based drugs. Reflecting this strategic shift, the company plans to change its name to Thalia Therapeutics plc, subject to shareholder approval at a 17 March 2026 general meeting in London.
The rebranding is intended to signal new leadership, a clearer strategic direction, and a focus on developing internally generated RNA assets alongside Nuvec, while also pursuing partnerships to build long-term shareholder value. Trading identifiers such as its LEI, ISIN and SEDOL will remain unchanged, existing share certificates will stay valid, and the company’s website and ticker will be updated following formal registration of the new name.
The most recent analyst rating on (GB:N4P) stock is a Sell with a £0.49 price target. To see the full list of analyst forecasts on N4 Pharma stock, see the GB:N4P Stock Forecast page.
Spark’s Take on GB:N4P Stock
According to Spark, TipRanks’ AI Analyst, GB:N4P is a Neutral.
The score is primarily held back by weak financial performance—persistent losses, ongoing cash burn, and shrinking equity—despite the benefit of having no debt. Technicals also point to a downtrend (negative MACD and price below key moving averages), while valuation is constrained by negative earnings and no dividend support.
To see Spark’s full report on GB:N4P stock, click here.
More about N4 Pharma
N4 Pharma plc is a UK-based biotechnology company focused on developing Nuvec, a proprietary gene delivery system designed to enable advanced therapies for cancer and other diseases. The business is transitioning into a therapeutic biotechnology model centered on innovative, high-value RNA-based therapeutics while continuing to progress its Nuvec delivery platform and expand its internal pipeline and partnering opportunities.
Average Trading Volume: 593,081
Technical Sentiment Signal: Hold
Current Market Cap: £4.58M
Learn more about N4P stock on TipRanks’ Stock Analysis page.